Tarter Krinsky & Drogin LLP is pleased to welcome Dr. Jing Xia as a Counsel in the Intellectual Property Group. For over ten years, she has concentrated her practice on the representation and counselling of mid to large size generic pharmaceutical clients, especially litigations arising under the Drug Price Competition and Patent Term Restoration Act (Hatch Waxman).

Dr. Xia regularly advises clients on product selection, formulation design around, clearance/invalidity opinions and litigations. She helps generic pharmaceutical companies navigate successfully through abbreviated new drug applications (ANDAs) and section 505(b)(2) filings.

A former bench scientist, Dr. Xia has helped clients to minimize risks and maximize returns on follow-on biologics (biosimilars) by providing counselling on major biological targets such as monoclonal antibodies, insulin, oncology products, anti-vascular endothelial growth factor products, anti-interleukin products and anti-tumor necrosis factor products.

Prior to joining Tarter Krinsky & Drogin LLP, Dr. Xia was affiliated with the law firms Axinn, Veltrop & Harkrider LLP, Goodwin Procter LLP and Budd Larner PC. She started her legal career at a biotech company, Affymetrix, which is a pioneer in microarray technology and genomic analysis.

Dr. Xia holds a Ph.D. degree in Pharmacology from Columbia University and was trained in both biotechnology and computer science from Zhejiang University. She is fluent in Mandarin Chinese.